Abrégé

The present invention relates to an optimized protein comprising the amino acid sequences as set forth in SEQ ID NO. 1; SEQ ID NO. 2; SEQ ID NO. 3; SEQ ID NO. 4; SEQ ID NO. 5; SEQ ID NO. 6; SEQ ID NO. 7; SEQ ID NO. 8; SEQ ID NO. 9; SEQ ID NO. 10; SEQ ID NO. 11; SEQ ID NO. 12; SEQ ID NO. 13; SEQ ID NO. 14; SEQ ID NO. 15; SEQ ID NO. 16; SEQ ID NO. 17; SEQ ID NO. 18; SEQ ID NO. 19; SEQ ID NO. 20, wherein said optimized protein comprises all essential amino acids in ratios suitable for human nutrition.

Classes IPC  ?

• A61K 38/39 - Peptides du tissu connectif, p. ex. collagène, élastine, laminine, fibronectine, vitronectine, globuline insoluble à froid [CIG]
• C07K 14/78 - Peptides du tissu connectif, p. ex. collagène, élastine, laminine, fibronectine, vitronectine ou globuline insoluble à froid [CIG]
• C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p. ex. glutathion

Abrégé

Provided are antibodies that specifically bind human astrovirus (HAstV) capsid spike protein. Fusion proteins and conjugates comprising such antibodies are also provided. Also provided are nucleic acids that encode one or both of the variable chain polypeptides of an antibody of the present disclosure, as are cells that include such nucleic acids. Also provided are compositions that include the antibodies of the present disclosure, including in some instances, pharmaceutical compositions. Methods of making and using the antibodies of the present disclosure are also provided. In certain aspects, provided are methods that include administering to an individual having or suspected of having a HAstV infection a therapeutically effective amount of an antibody, fusion protein or conjugate of the present disclosure.

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

The invention provides compositions of matter comprising a lipid enveloped virus capsid protein and a ribonucleic acid, as well as methods for using such compositions. In illustrative compositions, the lipid enveloped virus capsid protein envelops the ribonucleic acid so as to for a capsid that can inhibit the degradation of the ribonucleic acid (e.g. by RNAses). A method of delivering a ribonucleic acid into the cytoplasm of a mammalian cell is also provided. Typically, the method comprises the steps of combining the mammalian cell with a composition of matter described herein under conditions selected to allow the lipid enveloped virus capsid to contact the mammalian cell and deliver the ribonucleic acid into the cytoplasm of a mammalian cell.

Classes IPC  ?

• C12N 15/88 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation utilisant la micro-encapsulation, p. ex. utilisant des vésicules liposomiques
• A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p. ex. kinases (2.7)

Abrégé

A methodology to obtain in vitro large numbers of human induced regulatory T cells with specificity to the donor antigen, with a phenotype and stable suppressor function in the presence of pro-inflammatory cytokines, through of co-cultures of monocyte-derived dendritic cells and T cells “naïve”, both from genetically unrelated individuals (donor and recipient) is disclosed. The cells obtained with the present method are of CD4, CD25, CTLA-4 and FOXP3+ phenotype and show a specific suppressor function on donor antigen-specific T lymphocytes. These cells maintain their phenotype and stable suppressive function in presence of pro-inflammatory cytokines TNF-α and IL-6. The stability and the number obtained make them candidates as therapeutic tools for transplantation.

Classes IPC  ?

• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
• A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine

Abrégé

The present invention relates to a new composition of human recombinant antibody fragments in both single chain or Fab format, which is capable of completely neutralizing the venom of the scorpion Centruroides sculpturatus Ewing (C. sculpturatus. In particular the new composition comprises the scFv fragment 10FG2 (SEQ. ID. No: 1), which has broad cross-reactivity against various Mexican scorpion venom toxins, and the scFv fragment LR (SEQ. ID. No: 2), with more limited cross-reactivity. Alternatively, the new composition comprises the Fab 10FG2 fragment (SEQ. ID. No: 3 and SEQ.ID. No:4) and the Fab LR fragment (SEQ. ID. No: 5 and SEQ.ID. No 6). The two antibody fragments recognize independent epitopes, present in the two main toxins of the scorpion C. sculpturatus, so that they do not interfere with each other during their binding to the same, on the contrary the antibody fragments of the present invention complement the neutralizing activity.

Classes IPC  ?

• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• A61P 39/00 - Agents protecteurs généraux ou antipoisons

Abrégé

The present invention relates to the field of medicinal chemistry, with emphasis on the therapeutic effects of combining antioxidant and anticarcinogenic compounds, wherein the cytotoxic and antitumour properties of argentatins are combined with nordihydroguaiaretic acid (NDGA). These results are important because they offer the possibility of using triterpene compounds with anticarcinogenic activity in a reducing and non-oxidising atmosphere, favourable to cytotoxic action.

Classes IPC  ?

• A61P 35/00 - Agents anticancéreux
• A61K 31/56 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes
• A61K 36/28 - Asteraceae ou Compositae (famille de l'aster ou du tournesol), p. ex. camomille, chrysanthème matricaire, achillée ou echinacée

Abrégé

Disclosed herein are compositions and methods for treating a subject having an itch-related disorder, such as dermatological disorders or systemic disorders comprising itch. The methods may include determining the level of a biomarker in a biological sample from the subject. The biomarker may be selected from TRPV4 expression, lysophosphatidylcholine, and miRNA-146a expression, or a combination thereof. The subject may be identified as having the itch-related disorder when the level of the biomarker is greater in a sample from the subject than in a control. An anti-pruritic therapy may be administered to treat the subject having the itch-related disorder.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• A61P 17/04 - Antiprurigineux

Abrégé

The present invention relates to an optimised protein comprising the amino acids sequences established in SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 10, SEQ ID NO. 11, SEQ ID NO. 12, SEQ ID NO. 13, SEQ ID NO. 14, SEQ ID NO. 15, SEQ ID NO. 16, SEQ ID NO. 17, SEQ ID NO. 18, SEQ ID NO. 19 and SEQ ID NO. 20, wherein the optimised protein comprises, in suitable proportions, all the amino acids essential for human nutrition.

Classes IPC  ?

• C07K 14/78 - Peptides du tissu connectif, p. ex. collagène, élastine, laminine, fibronectine, vitronectine ou globuline insoluble à froid [CIG]
• A23L 33/18 - PeptidesHydrolysats de protéines

Abrégé

Provided are antibodies that specifically bind human astrovirus (HAstV) capsid spike protein. Fusion proteins and conjugates comprising such antibodies are also provided. Also provided are nucleic acids that encode one or both of the variable chain polypeptides of an antibody of the present disclosure, as are cells that include such nucleic acids. Also provided are compositions that include the antibodies of the present disclosure, including in some instances, pharmaceutical compositions. Methods of making and using the antibodies of the present disclosure are also provided. In certain aspects, provided are methods that include administering to an individual having or suspected of having a HAstV infection a therapeutically effective amount of an antibody, fusion protein or conjugate of the present disclosure.

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 31/12 - Antiviraux

Abrégé

The present invention relates to an entropic associative memory system for logging, recognising and returning distributed representations of images represented as finite functions. The images are stored in Associative Memory Logs (AMLs), which consist of tables with columns that correspond to the arguments and rows that correspond to their sampled values. The AMLs have an associated computational entropy, which defines their operating range. Each AML has an auxiliary input and output log, which consists of a table with the same dimensions and through which the content of the AMLs of a structured bus is read and written. The logging, recognition and memory retrieval operations correspond to the lambda, eta and gamma operations of the indeterminate relational computation.

Classes IPC  ?

• G06N 3/04 - Architecture, p. ex. topologie d'interconnexion

Abrégé

The present invention relates to methods and kits useful for determining, from the early stages of pregnancy, preferably before week 18 of gestation, the risk of a pregnant woman developing gestational diabetes, based on the concentration of a set of metabolites consisting of β-hydroxybutyrate, dodecanoylcarnitine (AC12), lactate, propionylcarnitine (AC3), arginine, isovalerylcarnitine (AC5), phenylalanine and leucine, in maternal serum samples.

Classes IPC  ?

• G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention describes a naturally occurring chemical compound, specifically guayulins A, B, C and D used in medicine having null cytotoxicity and genotoxicity on healthy lymphocyte cells. Said active compounds interfere with the inflammatory process and have antitumoral activity in human cancer cell lines, since they inhibit their growth through a senescence process.

Classes IPC  ?

• A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
• A61P 35/00 - Agents anticancéreux
• A61K 31/585 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine contenant des cycles lactone, p. ex. oxandrolone, bufaline
• A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol

Abrégé

A methodology to obtain large numbers of allospecific human Tr1 lymphocytes in vitro differentiated with phenotype and suppressive function stability in presence of proinflammatory cytokines, by using donor tolerogenic dendritic cells (DC10) derived from donor monocytes and from a not related receptor (allogeneic) naîve T cells cocultures. The obtained cells with the present methodology are characterized by the expression of a Tr1 regulatory phenotype (CD4+, CD49b+, LAG-3+), being high IL-10 producers, and also they express additional co-inhibitory molecules as PD1, TIM-3, CD39, CTLA-4 y TIGIT. Moreover, the cellular product obtained by this methodology is able to maintain a stable phenotype and suppressive function in presence of proinflammatory cytokines (IL-1β, IL-6, IFN-γ y TNF-α). The numbers, purity, and stability of the Tr1 obtained by this methodology, make them great candidates for their use as therapeutic tools in transplantation.

Classes IPC  ?

• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
• C12N 5/0784 - Cellules dendritiquesLeurs progéniteurs

Abrégé

Disclosed herein are compositions and methods for treating a subject having an itch-related disorder, such as dermatological disorders or systemic disorders comprising itch. The methods may include determining the level of a biomarker in a biological sample from the subject. The biomarker may be selected from TRPV4 expression, lysophosphatidylcholine, and miRNA-146a expression, or a combination thereof. The subject may be identified as having the itch-related disorder when the level of the biomarker is greater in a sample from the subject than in a control. An anti-pruritic therapy may be administered to treat the subject having the itch-related disorder.

Classes IPC  ?

• A61K 49/00 - Préparations pour examen in vivo
• A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention relates to a hybridisation method for the detection of nucleic acids, which comprises the steps of: (a) extracting a sample containing the genetic material to be detected, either DNA or RNA; (b) attaching magnetic particles to a synthetic oligonucleotide chain, wherein the surface of said magnetic particles is coated with a protein and said synthetic oligonucleotide chain has a binding tag, such that the binding of the protein to the oligonucleotide is called a functionalisation reaction, obtaining functionalised magnetic particles in this step; (c) incubating the sample containing the material to be detected (nucleic acids, either DNA or RNA) with a complementary strand oligonucleotide probe with a fluorescent tag, this reaction is referred to as competition reaction; and (d) making the functionalised magnetic particles obtained in step (b) react with a probe-target pair obtained in step (c), said step being referred to as the detection reaction.

Classes IPC  ?

• C12Q 1/6834 - Couplage enzymatique ou biochimique d’acides nucléiques à une phase solide

Abrégé

Provided are colored 1,4-benzoquinone compounds obtained by oxidation of precursor molecules from the venom of the scorpion Diplocentrus melici (Diplocentridae family). Schemes for the chemical synthesis of these compounds using reagents commercially available are also provided. Biological assays show that the red compound (3,5-dimethoxy-2-(methylthio)cyclohexa-2,5-diene-1,4-dione) is very effective at killing Staphylococcus aureus and that the blue compound (5-methoxy-2,3-bis(methylthio)cyclohexa-2,5-diene-1,4-dione) has remarkable activity against Mycobacterium tuberculosis. The blue compound is effective against multi-drug-resistant tuberculosis (MDR-TB) and is not detrimental to lung epithelium. Both compounds were found to be cytotoxic to human neoplastic cell lines and to mononuclear cells (PBMCs).

Classes IPC  ?

• C07C 323/22 - Thiols, sulfures, hydropolysulfures ou polysulfures substitués par des halogènes, des atomes d'oxygène ou d'azote ou par des atomes de soufre ne faisant pas partie de groupes thio contenant des groupes thio et des atomes d'oxygène, liés par des liaisons doubles, liés au même squelette carboné
• C07C 319/20 - Préparation de thiols, de sulfures, d'hydropolysulfures ou de polysulfures de sulfures par des réactions n'impliquant pas la formation de groupes sulfure
• A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
• A61P 31/04 - Agents antibactériens

Abrégé

55. The purpose of this invention is to form part of the therapeutic regimes used in breast cancer, particularly in tumours without expression of the extracellular domain of the EGFR protein, which is targeted by the drug Herceptin. The peptide of the invention can be used following resection and prior to commencing administration of chemotherapy.

Classes IPC  ?

• C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention relates to a process for obtaining polymer nanoparticles stabilised with a non-ionic polymer surfactant functionalised with a ligand, for receptor-mediated drug delivery. The distinctive feature of the invention is that said functionalisation is physical, through association in the stabiliser and the ligand, as opposed to other patents in which functionalisation is chemical. The invention also relates to the use of a methodology based on interfacial tension measurements and reported in scientific literature, to evaluate the capacity of the stabiliser to associate with ligand molecules.

Classes IPC  ?

• B82B 3/00 - Fabrication ou traitement des nanostructures par manipulation d’atomes ou de molécules, ou d’ensembles limités d’atomes ou de molécules un à un comme des unités individuelles
• B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p. ex. génie protéique ou administration de médicaments
• C08L 29/14 - Homopolymères ou copolymères d'acétals ou de cétals obtenus par polymérisation d'acétals ou de cétals non saturés ou par post-traitement des polymères d'alcools non saturés
• C07D 475/04 - Composés hétérocycliques contenant des systèmes cycliques ptéridine avec un atome d'oxygène lié directement en position 4 avec un atome d'azote lié directement en position 2
• C07C 43/02 - Éthers
• A61P 31/00 - Agents anti-infectieux, c.-à-d. antibiotiques, antiseptiques, chimiothérapeutiques

Abrégé

The present invention provides an oligopeptide that inhibits angiogenesis and vascular function which oligonucleotide has a length of 3 to 7 amino acids and comprises or consists of the sequence X2-X3-X4, wherein X2 is a basic or amide amino acid, X3 is a small amino acid and X4 is a basic amino acid, charged at neutral pH or the sequence X1-X2-X3-X4, wherein X1 is a polar non-charged amino acid and X2, X3 and X4 are identical to X2, X3 and X4 in X2-X3-X4, or the sequence X1-X2-X3-X4-X5-X6- X7, wherein X1, X2, X3 and X4 are identical to X1, X2, X3 and X4 in X1-X2-X3-X4, X5 is a small amino acid, X6 is a hydrophobic amino acid and X7 is a hydrophobic amino acid.

Classes IPC  ?

• A61K 38/04 - Peptides ayant jusqu'à 20 amino-acides dans une séquence entièrement déterminéeLeurs dérivés
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
• A61P 35/00 - Agents anticancéreux

Abrégé

Trypanosoma cruziTrypanosoma bruceiTrypanosoma brucei, said pharmaceutical composition including benznidazole and amphotericin B N-(L)-histidinamide with formula (I): (I)

Classes IPC  ?

• A61K 31/4168 - 1,3-Diazoles ayant un atome d'azote lié en position 2, p. ex. clonidine
• A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
• A61K 31/7056 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à cinq chaînons avec l'azote comme hétéro-atome d'un cycle
• A61P 33/02 - Antiprotozoaires, p. ex. pour le traitement de la leishmaniose, de la trichomonase, de la toxoplasmose

Abrégé

The present invention describes a naturally occurring chemical compound, specifically guayalins A, B, C and D used in medicine having null cytotoxicity and genotoxicity on healthy lymphocyte cells. Said active compounds interfere with the inflammatory process and have antitumoral activity in human cancer cell lines, since they inhibit their growth through a senescence process.

Classes IPC  ?

• C07C 13/62 - Hydrocarbures polycycliques ou leurs dérivés hydrocarbonés acycliques à cycles condensés à plus de trois cycles condensés
• C07C 13/66 - Hydrocarbures polycycliques ou leurs dérivés hydrocarbonés acycliques à cycles condensés à plus de trois cycles condensés le système cyclique condensé ne contenant que quatre cycles
• A61K 31/56 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes
• A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
• C07J 17/00 - Stéroïdes normaux contenant du carbone, de l'hydrogène, un halogène, ou de l'oxygène, ayant un hétérocycle contenant de l'oxygène non condensé avec le squelette du cyclopenta[a]hydrophénanthrène
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention refers to the use of the peptide defined by the amino acid sequence G-Y-Y-Y-P-S-D-P-N-T-F-Y-A-P-P-Y-S-A, named GK-1, to be used as an antitumor and antimetastatic agent or for the treatment of cancer, specifically of basal cell carcinoma, squamous cell carcinoma, transitional cell carcinoma, and adenocarcinoma, and preferably for the treatment of breast cancer.

Classes IPC  ?

• A61K 38/10 - Peptides ayant de 12 à 20 amino-acides
• A61P 35/00 - Agents anticancéreux

Abrégé

A hydrodynamically optimized mixer module, to be coupled to a deterministic hydrodynamic tool that allows pulsed polishing of optical surfaces is described. This module allows the supply of abrasive foam or fluid that enters the tool to be interrupted without impairing the operational stability of the polishing process and of said hydrodynamic tool. The mixer module includes at least one interrupter element for switching high-velocity fluids; a first inlet through which air is injected under pressure and in a controlled manner; a second inlet through which a polishing fluid is injected in a controlled manner, said polishing fluid filling a predetermined volume with a hydrodynamically optimized shape and being transferred to a mixing zone where, together with the pressure-injected air, an abrasive foam is produced that is injected into at least one rotational acceleration chamber of the hydrodynamic tool to which the mixer module is coupled.

Classes IPC  ?

• B24C 1/08 - Méthodes d'utilisation de jet abrasif en vue d'effectuer un travail déterminéUtilisation d'équipements auxiliaires liés à ces méthodes pour polir des surfaces, p. ex. en utilisant des abrasifs entraînés par un liquide
• B24C 3/32 - Machines ou dispositifs de traitement au jet abrasifInstallations de traitement au jet abrasif prévus pour le travail de pièces particulières, p. ex. de surface intérieure de blocs cylindres
• B24C 1/04 - Méthodes d'utilisation de jet abrasif en vue d'effectuer un travail déterminéUtilisation d'équipements auxiliaires liés à ces méthodes pour travailler uniquement certaines parties déterminées, p. ex. pour graver la pierre ou le verre
• B24C 7/00 - Équipement d'alimentation en matériau abrasifCommande de l'écoulement de la composition ou des autres caractéristiques physiques du jet abrasif

Abrégé

A method for preparing a supplement from mesenchymal cell cultures of Wharton's jelly including factors to favor the culture growth of cells from cutaneous system, in vitro, and to methods for producing epidermal, dermal, or cutaneous equivalents, and which may also be used as supplement for the proliferation and activation of autologous fibroblasts for subsequent intradcrmal use.

Classes IPC  ?

• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• C12P 21/00 - Préparation de peptides ou de protéines
• A61K 35/36 - PeauSystème pileuxOnglesGlandes sébacéesCérumenÉpidermeCellules épithélialesKératinocytesCellules de LangerhansCellules ectodermiques
• A61L 27/54 - Matériaux biologiquement actifs, p. ex. substances thérapeutiques
• A61L 27/58 - Matériaux au moins partiellement résorbables par le corps
• A61L 27/60 - Matériaux utilisables pour la peau artificielle
• A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
• C12N 5/077 - Cellules mésenchymateuses, p. ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
• A61K 35/33 - Fibroblastes
• C12N 5/073 - Cellules ou tissus embryonnairesCellules fœtales ou tissus fœtaux
• A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires

Abrégé

Provided are colored 1,4-benzoquinone compounds obtained by oxidation of precursor molecules from the venom of the scorpion Diplocentrus melici (Diplocentridae family). Schemes for the chemical synthesis of these compounds using reagents commercially available are also provided. Biological assays show that the red compound (3,5-dimethoxy-2-(methylthio)cyclohexa-2,5-diene-1,4-dione) is very effective at killing Staphylococcus aureus and that the blue compound (5-methoxy-2,3-bis(methylthio)cyclohexa-2,5-diene-1,4-dione) has remarkable activity against Mycobacterium tuberculosis. The blue compound is effective against multi-drug-resistant tuberculosis (MDR-TB) and is not detrimental to lung epithelium. Both compounds were found to be cytotoxic to human neoplastic cell lines and to mononuclear cells (PBMCs).

Classes IPC  ?

• A61P 31/04 - Agents antibactériens
• A61P 35/00 - Agents anticancéreux
• C07C 50/04 - Benzoquinones, c.-à-d. C6H4O2
• C07C 50/26 - Quinones contenant des groupes dont les atomes d'oxygène sont liés par liaison simple à des atomes de carbone

Abrégé

The disclosure provides nucleic acids encoding variant polypeptides having pesticidal activity against insect pests, including Lepidoptera and Diptera. Particular embodiments provide isolated nucleic acids encoding Cyt1A variant polypeptides, pesticidal compositions, DNA constructs, and transformed microorganisms and plants comprising a nucleic acid of the embodiments. These compositions find use in methods for controlling pests, particularly Diptera pests.

Classes IPC  ?

• A61K 38/00 - Préparations médicinales contenant des peptides
• C07K 14/325 - Peptides de cristal de Bacillus thuringiensis, c.-à-d. delta-endotoxines
• A01N 63/10 - Animaux Substances produites par des animaux ou obtenues à partir de ceux-ci

Abrégé

Paracoccus denitrificans321OParacoccus denitrificansParacoccus denitrificans being carried out in anaerobic conditions.

Classes IPC  ?

• C12N 1/20 - BactériesLeurs milieux de culture
• C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• C12R 1/01 - Bactéries ou actinomycètes

Abrégé

The invention relates to an optical radiometer with precise aiming, for measuring radiative fluxes emitted by radiant sources at temperatures from 25 to 6000 °C. The optical radiometer uses wide-radiation-spectrum optical components and thermoelectric and electronic devices which provide same with linear behaviour. The optical radiometer is calibrated with a radiation pattern, with temperatures at which the radiation template can operate (25 to 1400 °C); however the linear behaviour of the radiometer allows the calibration thereof to remain valid to precisely measure radiative fluxes emitted by bodies at temperatures of up to 6000 °C, which represents high radiative fluxes.

Classes IPC  ?

• G01J 5/08 - Dispositions optiques
• G01J 5/16 - Aménagements relatifs à la jonction froideCompensation de l'influence de la température ambiante ou d'autres variables

Abrégé

in vitroin vitro method for encapsidating dsRNA of varying length in plant virus capsids (VLPs) comprising three steps, namely purification, assembly and stabilisation, is also described.

Classes IPC  ?

• C12N 15/86 - Vecteurs viraux

Abrégé

Hybrid proteins with cytochrome P450 activity and which are encapsulated in a nanocapsid (nanoparticles charged with cytochrome P450 activity) are designed and synthesized, these hybrid proteins being immunologically inert and recognized by breast cancer cells.

Classes IPC  ?

• C12N 15/86 - Vecteurs viraux
• A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
• A61K 9/51 - Nanocapsules
• A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 38/44 - Oxydoréductases (1)
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• C07K 14/24 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant d'Entérobacteriaceae (F), p. ex. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• C12N 9/02 - Oxydoréductases (1.), p. ex. luciférase

Abrégé

The present invention relates to peptides which have anti-inflammatory activity, anti-angiogenic activity and/or antimicrobial activity, to a medicament or a pharmaceutical composition comprising such peptides, and to the use thereof in the prevention or treatment of inflammatory diseases, and more particularly inflammatory diseases caused by or related to microbial infections, or in the prevention or treatment of angiogenesis-related diseases.

Classes IPC  ?

• C07K 14/46 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61P 31/04 - Agents antibactériens
• A61P 31/10 - Antifongiques
• A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe

Abrégé

The present invention relates to a hydrodynamically optimised mixer module to be coupled to a deterministic hydrodynamic tool for the pulsed polishing of optical surfaces, which is configured such that the supply of abrasive foam or fluid can be interrupted without impairing the operational stability of the polishing process and of the hydrodynamic tool. The mixer module comprises: at least one interrupter element for interrupting high-speed fluids, which may be disposed inside or outside the body of the mixer module for the purpose of interrupting the controlled-pressure and -flow supply of the abrasive foam; a first inlet through which air is injected under pressure and in a controlled manner; a second inlet through which a polishing fluid is injected in a controlled manner, said polishing fluid filling a previously calculated space with an optimised hydrodynamic shape and being transferred to a mixing zone where, together with the pressure-injected air, the abrasive foam is produced that is injected into a module of at least one rotational acceleration chamber of the hydrodynamic tool. The invention also relates to a method for carrying out the deterministic polishing process.

Classes IPC  ?

• B24C 7/00 - Équipement d'alimentation en matériau abrasifCommande de l'écoulement de la composition ou des autres caractéristiques physiques du jet abrasif
• B24C 1/08 - Méthodes d'utilisation de jet abrasif en vue d'effectuer un travail déterminéUtilisation d'équipements auxiliaires liés à ces méthodes pour polir des surfaces, p. ex. en utilisant des abrasifs entraînés par un liquide

Abrégé

The present invention relates to a modular piece for constructing reefs, which comprises a main body having a lower section and an upper section, wherein said lower section comprises at least one prism having regular or irregular geometry, the prism having at least one first stabiliser that projects radially from said lower section, the at least one first stabiliser comprising a quadrangular longitudinal section or a triangular longitudinal section, and wherein the upper section comprises at least one prism having regular or irregular geometry.

Classes IPC  ?

• A01K 61/77 - Berges ou récifs artificiels pour la pêche de forme monolithique, p. ex. blocs
• E02B 3/04 - Ouvrages, appareils ou procédés pour la protection des berges, des côtes ou des ports

Abrégé

The present invention relates to a robot hand with ambidextrous ability, comprising at least one actuator to provide the power required to move at least one end or finger attached to the upper end of the actuator, by means of a rotating movable support; and the actuator includes at its lower end a base that keeps the actuator fixed to other parts of the robot hand, wherein the base forms the static point of reference on which the finger being moved changes position; and a transmission system for transmitting the power provided by the actuator to the finger, allowing the finger to move.

Classes IPC  ?

• B25J 15/00 - Têtes de préhension
• A61F 2/58 - CoudesPoignets

Abrégé

The invention relates to a method for preparing a supplement from mesenchymal cell cultures of Wharton’s jelly, which comprises factors that promote the growth of cell cultures of the cutaneous system, in vitro, and to methods for producing epidermal, dermal or cutaneous equivalents using the supplement. The invention also relates to the use of the supplement for the proliferation and activation of autologous fibroblasts for subsequent intradermal use.

Classes IPC  ?

• C12N 5/0775 - Cellules souches mésenchymateusesCellules souches dérivées du tissu adipeux
• A61K 35/51 - Cordon ombilicalSang de cordon ombilicalCellules souches ombilicales
• A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
• A61L 27/38 - Cellules animales
• A61L 27/54 - Matériaux biologiquement actifs, p. ex. substances thérapeutiques

Abrégé

Disclosed herein are transgenic plants comprising heterologous molecular chaperone genes and insecticidal Bacillus thuringiensis (Bt) genes capable of conferring enhanced Bt insecticidal activity to insects. The disclosure further relates to methods of producing transgenic plants, enhancing efficacy of a Bt toxin and controlling insect populations in areas of cultivation using transgenic plants co-expressing a heterologous molecular chaperone gene and a Bt gene.

Classes IPC  ?

• C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales
• C12N 15/75 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes procaryotes autres que E. coli, p. ex. Lactobacillus, Micromonospora pour Bacillus
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens

Produits et services

Teaching Spanish as a foreign language, teacher training, teacher training, organization of pedagogical tests and exhibitions for cultural or educational purposes; editing of educational videos and texts.

Abrégé

The present invention relates to a method for the gas-phase acid treatment of lignocellulosic materials, including cellulose mass, hemicellulose mass and lignin mass, in order to obtain high yields of glucose, C5 monosaccharides and lignosulfonates. Said method includes a step of treating lignocellulosic materials allowing the subsequent enzymatic hydrolysis thereof, at treatment temperatures no greater than 160°C, using a reduced number of devices, such as a single stirred reactor, and with low operating costs.

Classes IPC  ?

• C08B 15/08 - Fractionnement de la cellulose, p. ex. séparation des cristallites de cellulose
• D21C 3/06 - Réduction en pâte des matières contenant de la cellulose avec des acides, des sels acides ou des anhydrides d'acide anhydride sulfureuxRéduction en pâte des matières contenant de la cellulose avec des acides, des sels acides ou des anhydrides d'acide acide sulfureuxRéduction en pâte des matières contenant de la cellulose avec des acides, des sels acides ou des anhydrides d'acide bisulfites

Abrégé

The invention relates to a biosensor device for detecting and quantifying biomolecules contained in a sample of body fluid, using an immunodetection method. That is, the biomolecules to be detected should have an antibody for specific recognition of the biomolecules of interest, or an antibody for specific recognition should be able to be made from the biomolecules of interest and should be marked for recognition. The biosensor can detect and quantify a single type of biomolecule or antigen (single detection) or a plurality of biomolecules or antigens (multiple detection). For this purpose, the biosensor comprises: a main body formed by a substrate that includes a plurality of devices that communicate with each other by means of micro-channels; magnetic displacement means disposed below the plurality of devices, which are configured for the use of magnetic fields; and a lens disposed on top of one of the devices.

Classes IPC  ?

• G01N 21/00 - Recherche ou analyse des matériaux par l'utilisation de moyens optiques, c.-à-d. en utilisant des ondes submillimétriques, de la lumière infrarouge, visible ou ultraviolette
• G01N 27/00 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques
• G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres
• G01N 33/551 - Support inorganique
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet

Abrégé

Dewar flasks are containers used to transport materials that have to be kept at a low temperature and protected against vibration, shaking, impact, oscillation and/or any other external disturbance that could interfere with thermodynamic stability. However, if the Dewar flask is opened arbitrarily, such as for customs inspections during air transportation, without knowledge of the material contained therein, this could affect not only the low temperature inside the container, but also the intrinsic properties of the material therein. The device or container of the present invention is suitable for materials that have to be isolated from changes in temperature and/or external disturbances and can be used to transport said materials under suitable conditions from one site to another, including over long distances and intercontinental journeys, without any risk of damage from handling or external disturbances and without any thermal risk.

Classes IPC  ?

• B65D 81/38 - Réceptacles, éléments d'emballage ou paquets pour contenus présentant des problèmes particuliers de stockage ou de transport ou adaptés pour servir à d'autres fins que l'emballage après avoir été vidés de leur contenu avec isolation thermique

Abrégé

The invention relates to the use of the compound (2,3-dihydro-2-thioxo-3-benzoxazole methylamino)-salicylic acid (4-DTS) derived from 2-mercaptobenzoxazole as an antibiotic agent that specifically inhibits, in the low micromolar range, bacterial Ribonuclease P (RNase P), as well as inhibiting the growth of Escherichia coli bacteria. Said 4-DTS compound can be used to produce a drug for the treatment of infectious diseases caused by gram-negative bacteria.

Classes IPC  ?

• C07D 263/58 - BenzoxazolesBenzoxazoles hydrogénés avec des hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile, liés directement en position 2
• A61K 31/423 - Oxazoles condensés avec des carbocycles
• A61P 31/04 - Agents antibactériens

Abrégé

The invention relates to novel recombinant polynucleotides isolated from genes ancut1 and ancut2, which encode functional recombinant polypeptides that can degrade polyester plastics such as PET, of cutinase enzymes from Aspergillus nidulans. The invention also relates to expression vectors comprising said polynucleotides, to recombinant microorganisms comprising said vectors, to methods for the production and purification of said functional recombinant polypeptides, and to methods for degrading polyester plastics using compositions comprising the aforementioned functional recombinant polypeptides and microorganisms.

Classes IPC  ?

• C12N 15/09 - Technologie d'ADN recombinant
• C12N 1/19 - LevuresLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• C12N 9/18 - Hydrolases agissant sur les esters d'acides carboxyliques
• C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p. ex. glutathion

Abrégé

The disclosure provides nucleic acids encoding variant polypeptides having pesticidal activity against insect pests, including Lepidoptera and Diptera. Particular embodiments provide isolated nucleic acids encoding CytlA variant polypeptides, pesticidal compositions, DNA constructs, and transformed microorganisms and plants comprising a nucleic acid of the embodiments. These compositions find use in methods for controlling pests, particularly Diptera pests.

Classes IPC  ?

• A01N 63/02 - Substances produites par, ou obtenues à partir de micro-organismes ou d'animaux
• C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• C07K 14/195 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries
• C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains

Abrégé

The present invention relates to the use of the peptide having the amino acid sequence G-Y-Y-Y-P-S-D-P-N-T-F-Y-A-P-P-Y-S-A and named GK-1 for use as an antitumoral and antimetastatic agent for the treatment of cancer, more specifically of basal cell cancer, squamous cell cancer, transitional cell carcinoma and adenocarcinoma, and preferably for the treatment of breast cancer.

Classes IPC  ?

• A61K 38/10 - Peptides ayant de 12 à 20 amino-acides

Produits et services

Teaching Spanish as a foreign language, teacher training, teacher training, organization of pedagogical tests and exhibitions for cultural or educational purposes; editing of educational videos and texts

Produits et services

Publications. Teaching Spanish as a foreign language, teacher training, arranging educational tests and exhibitions for cultural or educational purposes; Publication of texts and educational videos. Scientific and technological services as well as research and design services relating thereto; Industrial analysis and research; Design and development of computers and computer software.

Abrégé

The invention relates to a process for the production of organofluoride quarternary cationic salts, comprising the following steps: a) adding a base; b) suspending the base in a suitable polar organic solvent; c) including an alkylating agent via slow addition; d) slowly adding an organofluoride substrate; e) heating the reaction mixture produced in the preceding step d); f) bringing the reaction mixture to ambient temperature; g) filtering the reaction mixture under vacuum, washing the remaining solid with a polar organic solvent; h) accelerating the evaporation of the solvent to complete dryness, producing a whitish solid; i) washing the solid with a non-polar organic solvent; j) purifying the compound produced in the preceding step i), using a polar or non-polar organic solvent, wherein the cationic salts produced with this method are used as chemical tracers to determine the heterogeneity in carbonate-type oil fields.

Classes IPC  ?

• C07C 211/63 - Composés d'ammonium quaternaire ayant des atomes d'azote quaternisés liés à des atomes de carbone acycliques
• C07C 211/52 - Composés contenant des groupes amino liés à un squelette carboné ayant des groupes amino liés à des atomes de carbone de cycles aromatiques à six chaînons du squelette carboné ayant des groupes amino liés à un seul cycle aromatique à six chaînons le squelette carboné étant substitué de plus par des atomes d'halogène ou par des groupes nitro ou nitroso
• C09K 8/58 - Compositions pour les méthodes de récupération assistée pour l'extraction d'hydrocarbures, c.-à-d. pour améliorer la mobilité de l'huile, p. ex. fluides de déplacement

Abrégé

The present invention relates to extracts/fractions and compounds obtained from same, which comprise diterpenes, isolated from Salvia amarissima, with a novel, non-conventional carbon skeleton, and to the pharmacological properties thereof. The invention also relates to extracts and/or standardised fractions and compounds obtained from same, of the class of diterpenes that can be used as modulators of multidrug resistance in breast cancer.

Classes IPC  ?

• C07D 307/93 - Composés hétérocycliques contenant des cycles à cinq chaînons comportant un atome d'oxygène comme unique hétéro-atome du cycle condensés en ortho ou en péri avec des carbocycles ou avec des systèmes carbocycliques condensés avec un cycle autre qu'un cycle à six chaînons
• C07D 493/10 - Systèmes condensés en spiro
• A61K 36/537 - Salvia (sauge)
• A61K 31/365 - Lactones
• A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases

Abrégé

The present invention relates to a catalytic system using a new family of pyrrole-based ligands, which allows molecules having an olefin terminal in the structure to be obtained from the corresponding aryl halide, with improved yields and safer reaction conditions.

Classes IPC  ?

• C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 413/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 417/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 421/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de sélénium, de tellure ou d'halogènes comme hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C01G 55/00 - Composés du ruthénium, du rhodium, du palladium, de l'osmium, de l'iridium, ou du platine
• B01J 23/44 - Palladium

Abrégé

The contamination of receiving water bodies by heavy metals due to anthropomorphic activities is of great significance to human health. There are metals that have a high capacity to form radicals that alter cellular functions when they exceed certain concentrations, for example, a prolonged exposure to concentrations greater than 20 mg of copper/L promotes the development of cancer. The invention relates to a thermoplastic matrix of chitosan (Ch) and polycaprolactone (PCL) for the removal of heavy metals in waste water, which, used in a ratio of 2:1 p/p respectively, offers a capacity of 62.5 mg Cu2+/g adsorbent (ads) in continuous processes with a HRT of less than 2 hours, and which permits various reuse cycles.

Classes IPC  ?

• C02F 1/28 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par absorption ou adsorption
• C02F 1/58 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par élimination de composés spécifiés dissous
• C02F 1/62 - Composés des métaux lourds
• B01J 20/22 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance organique
• B01J 20/24 - Composés macromoléculaires d'origine naturelle, p. ex. acides humiques ou leurs dérivés
• B01J 20/26 - Composés macromoléculaires synthétiques

Abrégé

The present invention relates to a modular solar air heater comprising: a heating module that captures the greatest quantity of solar radiation so as to be able to heat above ambient temperature the air circulating therein; a first diffuser located at one end of the heating module to allow improved distribution of the airflow and more homogeneous heating; and a second diffuser located at the other end of the heating module, for collecting the warm air flow and concentrating same on the outlet of the solar collector. The two diffusers do not form part of the heating module, thus maximum use is made of the solar capture area.

Classes IPC  ?

• F24J 2/20 - le fluide vecteur circulant entre des plaques
• F24J 2/46 - Parties constitutives, détails ou accessoires de collecteurs de chaleur solaire

Abrégé

Process and system for identifying and quantifying helminth eggs in water, sludge, biosolid and/or excreta samples among others, from images comprising filtering the images with an anisotropic filter maintaining the borders of the images, obtaining filtered images; filtering the filtered images applying Laplacian of Gaussian detecting changes in the filtered images, and obtaining binarized images; separating the binarized images by means of a filtered distance field Watershed filter, obtaining the images; filtering the images eliminating objects by perimeter compactness, considering the size of the objects in the images filtered again and separating the differences to avoid false positives, obtaining images with identified objects; characterizing the objects identified in the images segmenting the objects by means of gray profiles; and classifying the characterized objects according to a statistic classifier for identifying and quantifying different species of helminth eggs.

Classes IPC  ?

• G06T 5/20 - Amélioration ou restauration d'image utilisant des opérateurs locaux
• G06T 5/40 - Amélioration ou restauration d'image utilisant des techniques d'histogrammes
• G06K 9/46 - Extraction d'éléments ou de caractéristiques de l'image
• G06T 7/60 - Analyse des attributs géométriques
• G06T 7/40 - Analyse de la texture
• G06K 9/00 - Méthodes ou dispositions pour la lecture ou la reconnaissance de caractères imprimés ou écrits ou pour la reconnaissance de formes, p.ex. d'empreintes digitales
• G06T 7/62 - Analyse des attributs géométriques de la superficie, du périmètre, du diamètre ou du volume
• G06T 7/00 - Analyse d'image

Abrégé

The present invention provides osteogenic peptides derived from cementum attachment protein (HACD1/CAP) and another derived from cementum protein 1 (CEMP1), and pharmaceutical compositions of said peptides for the prevention and treatment of osteopenia and osteoporosis. These peptides increased bone mineral density in an osteoporotic model, without side effects in vivo, demonstrating clinical effectiveness in the prevention and treatment of osteopenia and osteoporosis in vivo, as well as in bone repair and/or regeneration.

Classes IPC  ?

• A61K 38/04 - Peptides ayant jusqu'à 20 amino-acides dans une séquence entièrement déterminéeLeurs dérivés
• A61P 19/10 - Médicaments pour le traitement des troubles du squelette des maladies osseuses, p. ex. rachitisme, maladie de Paget de l'ostéoporose

Abrégé

The present invention relates to the field of biomacromolecular crystallography, as well as to methods and devices used for the nucleation and growth of biological macromolecule crystals. Unlike existing devices in the prior art, the electro-assisted crystallisation cell described in this invention has a different conception, since the crystallisation cell is a novel design based on a plastic material (polyethylene, PET).

Classes IPC  ?

• C30B 7/02 - Croissance des monocristaux à partir de solutions en utilisant des solvants liquides à la température ordinaire, p. ex. à partir de solutions aqueuses par évaporation du solvant
• C30B 30/02 - Production de monocristaux ou de matériaux polycristallins homogènes de structure déterminée, caractérisée par l'action de champs électriques ou magnétiques, de l'énergie ondulatoire ou d'autres conditions physiques spécifiques en utilisant des champs électriques, p. ex. par électrolyse

Abrégé

The instant invention is related with new perimidine derivatives synthesized via direct condensation between naphthalene-1,8-diamine and itaconic or citraconic anhydrides at low temperature. The targeting itaco-perinone (IP) molecule formed via double low temperature cyclization has fluorescence properties emitting white light intensively. Besides, 9-methylene-8H-pyrrolo[1,2-a]perimidin-10(9H)-one is copolymerizable with several kind of organic monomer compounds via free radical mechanism maintaining the ability to emit white light even within the polymer film.

Classes IPC  ?

• C07D 487/06 - Systèmes condensés en péri
• C09K 11/06 - Substances luminescentes, p. ex. électroluminescentes, chimiluminescentes contenant des substances organiques luminescentes
• C08F 220/14 - Esters méthyliques

Abrégé

The invention relates to a pharmaceutical composition for veterinary use, comprising a suspension of progesterone in a polymer system, said composition comprising: an effective quantity of progesterone of between 2% and 20% m/v; an effective quantity of a copolymer in suspension of between 3% and 60% m/v; an effective quantity of polyethylene glycol of between 10% and 30% m/v, in which the molecular weight of the polyethylene glycol is between 400 and 20000 Da; a sufficient quantity for 50ml of a solvent selected from a mixture of water/ethanol, a mixture of N-methylpyrrolidone/water, or a mixture of N-methylpyrrolidone/water/ethanol. According to the invention, the pharmaceutical composition is administered parenterally as a modified release composition, and has in situ gelling properties. The pharmaceutical composition can be used to control fertility in animal species.

Classes IPC  ?

• A61K 31/57 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone

Abrégé

In the present invention, hybrid proteins with cytochrome P450 activity and which are encapsulated in a nanocapsid (nanoparticles charged with cytochrome P450 activity) are designed and synthesised, these hybrid proteins being immunologically inert and recognised by breast cancer cells. The method consists in encapsulating cytochrome P450 molecules in virus capsids or biopolymer nanoparticles. In one case, the gene that codes for cytochrome P450 enzyme is fused with the nucleotide sequence of a truncated version of bacteriophage P22 scaffolding protein. The proteins are expressed heterologously and the capsids containing cytochrome P450 are purified. The enzyme nanoparticles are coated with bifunctional dendritic polyethylene glycol and, lastly, functionalised with the cyclic peptide Arg-Gly-Asp-D-Phe-Cys or another ligand so as to be recognised by ανβ3/5 integrin or another breast tumor cell receptor. This invention specifically provides tumor cells with cytochrome P450 activity that activates more efficiently and in the site required by prodrugs used in chemotherapy.

Classes IPC  ?

• A61K 9/64 - Revêtements organiques contenant des protéines ou leurs dérivés
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• C12N 15/86 - Vecteurs viraux
• A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases

Abrégé

Sus scrofa), as well as recognizing the receptor DEC-205 in dentritic cells and cell lines in humans. In addition, the invention is used to quickly produce a specific humoral immune response against Hemaglutinina H5 of the H5N2-type avian flu virus.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

The invention relates to an associative memory system for saving, recognising and returning contents represented as attribute-value structures, in which said structures are also the indices for directly accessing the memory. The aforementioned contents consist of acoustic or visual images or other information represented as discrete functions with finite domains, or families of finite abstractions or functions. The information is stored in a rectangular grid, in a parametric manner, for m attributes with n values. Each state of the grid represents one content or one abstraction and has a unique descriptor and an associated entropy, the definitions of which also form part of the present application. The mechanism is based on the operations of (a) diagrammatic abstraction, in order to record information in the memory, and (b) diagrammatic reduction in order to recognise and/or extract information from the memory, the definitions of which form part of the content of the present application. The invention also includes the logic structure of the memory and its control program. The memory can be simulated in an ordinary digital computer or constructed as an integrated circuit, either as part of a central processing unit or as an independent integrated circuit.

Classes IPC  ?

• G06F 17/30 - Recherche documentaire; Structures de bases de données à cet effet
• G11C 15/00 - Mémoires numériques dans lesquelles l'information, comportant une ou plusieurs parties caractéristiques, est écrite dans la mémoire et dans lesquelles l'information est lue au moyen de la recherche de l'une ou plusieurs de ces parties caractéristiques, c.-à-d. mémoires associatives ou mémoires adressables par leur contenu

Abrégé

The invention relates to a method for synthesising vanillylamides of organic acids, based on vanillin oxime, inorganic salts of vanillylamine or based on organic salts of vanillylamine having organic acids. The method involves: the chemical synthesis of vanillylamine organic salts based on the hydrogenation of the vanillin oxime in the presence of an organic acid; the release of vanillylamine inorganic salts in the presence of a base or carbonate and an organic acid; and an enzymatic condensation of the two elements that form the organic salt, the vanillylamine and the organic acid, in order to bring about the synthesis of organic acid vanillylamides. The organic acid used for the reaction can be any organic acid: natural or synthetic, saturated, linear or branched, having substituents such as hydroxyl groups or others. The reactions can be carried out independently or in sequence. These capsaicinoid compounds, components similar to capsaicin or vanillylamides can be used as a pungent material, irritant, in pharmaceutical products, as additives in food, in cosmetics, among others.

Classes IPC  ?

• C12P 13/02 - Amides, p. ex. chloramphénicol
• C07C 231/00 - Préparation d'amides d'acides carboxyliques
• C07C 233/00 - Amides d'acides carboxyliques

Abrégé

The present invention relates to a device for surface recording of the masseter muscles comprising: a 2-channel electromyograph machine; a first set of three surface electrodes and a second set of three surface electrodes, wherein with the aid of a head support the first set of surface electrodes is placed on the right side of the head of a subject under study, while the second set of surface electrodes is placed on the left side, both sets or electrodes are disposed at the level of the masseter muscles of the subject under study, whereby the EMG surface activity generated during a test conducted on the subject under study is registered through both sets of surface electrodes and an EMG signal is sent to the electromyograph machine through a first and a second channel for processing and subsequent transfer to a personal computer that allows the analysis of the processed data; and a power supply that provides the power necessary for the proper and optimum device performance.

Classes IPC  ?

• A61B 5/0488 - Electromyographie

Abrégé

The invention relates to a method for obtaining isogenic derivatives of any variety of maize, having improved properties, such as resistance to adverse environmental conditions, for example drought and high temperatures, while offering improved growth and grain yield. The method of the invention for obtaining said derivatives of any variety of maize produces an isogenic maize line, i.e. plants that have the same genetic make-up as the original variety, but that are characterised in that they overexpress some genes, in particular associated with osmoprotection, thermotolerance and protection of photosynthetic activity. The invention is particularly characterised in that it offers genetic improvement without incurring the insertion of heterologous DNA (autogenic or isogenic maize) since it comprises the use of a gene from the same plant, which is simply being overexpressed.

Classes IPC  ?

• C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales

Abrégé

The invention relates to a technological system for online knowledge management integrated by a set of processes used for knowledge management, the system being characterized in that it comprises: a registration process; contribution creation; revision; and/or editing; publication; processing for interconnection; and optionally navigation. The novel system described in this invention provides a tool for use in the field of education and/or training, enabling strategies for knowledge management to be improved at the same time as providing a public having a particular interest with access to information by means of the abovementioned features.

Classes IPC  ?

• G06Q 50/00 - Technologies de l’information et de la communication [TIC] spécialement adaptées à la mise en œuvre des procédés d’affaires d’un secteur particulier d’activité économique, p. ex. aux services d’utilité publique ou au tourisme
• G06F 17/20 - Manipulation de données en langage naturel

Abrégé

The invention relates to hydrosoluble compounds derived from benzimidazole and represented by the general formula (I), in which: Y1 and Y2 are independently O or S, and at least one of Y1 and Y2 is O; R1 and R2 are independently hydrogen or a cation, both are hydrogen or both are cations; R3 is an alkyl with between 1 and 4 carbon atoms; R4 and R5 are independently halogen or a -QR6 alkoxide; and R6 is an aryl having between 6 and 10 carbon atoms linked in position 5- or 6- of the benzimidazole nucleus.

Classes IPC  ?

• C07F 9/09 - Esters des acides phosphoriques
• C07D 235/22 - BenzimidazolesBenzimidazoles hydrogénés avec des hétéro-atomes liés directement aux atomes d'azote du cycle
• A61K 31/66 - Composés du phosphore
• A61K 31/4184 - 1,3-Diazoles condensés avec des carbocycles, p. ex. benzimidazoles

Abrégé

The invention relates to nanostructured systems as thermal protectors of functional ingredients, which are formed by nanoparticulate systems, wherein said nanoparticles can be nanocapsules or nanospheres. The nanoparticles have an average particle size no greater than 350 nm, and comprise; (a) a polymer as a protective membrane; (b) functional or active ingredients that are included in the core of the nanocapsule for the protection thereof; (c) stabilising agents; and (d) the use of carrier solutions based on polymers for food purposes.

Classes IPC  ?

• B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p. ex. génie protéique ou administration de médicaments
• B82Y 30/00 - Nanotechnologie pour matériaux ou science des surfaces, p. ex. nanocomposites
• A23L 1/29 - Modification de la qualité nutritive des aliments; Produits diététiques ( A23L 1/09 a priorité;substituts diététiques du sel A23L 1/22)
• C08L 67/04 - Polyesters dérivés des acides hydroxycarboxyliques, p. ex. lactones

Abrégé

The present invention relates to an enzymatic polymerization process that comprises the steps of: (a) adding to a reactor from 10 to 3000 parts by weight of a monomer, which is mixed with a pH and salinity buffer or regulator solution; (b) adding to 50 parts of water from 1 to 10 parts of a solution of a strong base in order to dissolve the multi-substituted phenyl monomer and maintaining same in aqueous dispersion; (c) conditioning the above reaction mixture at a temperature of between 5°C and 60°C, stirring said reaction mixture at a speed of between 10 and 1000 rpm; (d) adding an oxidizing agent whilst the solution is being heated and stirred; (e) adding the enzyme units in a quantity ranging from 0.1% to 40.0% by weight relative to the quantity of multi-substituted phenyl precursor monomer; (f) maintaining the reaction conditions for such a period of time as the reaction lasts, which period of time may be from 1 hour to 72 hours; (g) precipitating the mixture, changing the polarity of the medium upon completion of the polyoxidation reaction for the separation and purification of the multi-substituted polymer, and to that end a cold polar solvent is added; (h) leaving the mixture resulting from the above step (g) to settle for 12 hours at ambient temperature. The present invention also relates to the polymer resulting from the enzymatic polymerization process, which has been synthesized by polyoxidation of the multi-substituted phenyl monomer that is a benzene derivative substituted in at least one position and in up to four of its positions by various functional chemical groups.

Classes IPC  ?

• C08G 61/10 - Composés macromoléculaires contenant uniquement des atomes de carbone dans la chaîne principale de la molécule, p. ex. polyxylylènes uniquement des atomes de carbone aromatiques, p. ex. polyphénylènes
• C08G 65/44 - Composés macromoléculaires obtenus par des réactions créant une liaison éther dans la chaîne principale de la macromolécule à partir de composés hydroxylés ou de leurs dérivés métalliques dérivés des phénols par oxydation des phénols
• C12P 7/22 - Préparation de composés organiques contenant de l'oxygène contenant un groupe hydroxyle aromatiques
• C12N 9/02 - Oxydoréductases (1.), p. ex. luciférase
• C09K 15/08 - Compositions anti-oxydantesCompositions inhibant les modifications chimiques contenant des composés organiques contenant de l'oxygène contenant une fraction phénol ou quinone

Abrégé

The invention relates to a pharmaceutical composition comprising: at least one antiparasitic active ingredient for providing the pharmacological therapeutic effect; an agent having bio-adhesive properties that helps to reduces the motility and reproduction of the parasites, increasing the period of time for which the product remains on the skin of the animals; an agent having permeation- or absorption-promoting properties that contributes to increasing the cutaneous permeability of the active ingredient; a surfactant agent that is absorbed in an oil-water interface, and as a result, the molecules of said surfactant agent form a kind of bridge between the polar phase (water) and the non-polar phase (oil), thereby making the transition between both phases less abrupt; an oil which will form the oily phase of the emulsion, and which will incorporate the active ingredient; and a neutralising agent.

Classes IPC  ?

• A61K 9/107 - Émulsions
• A61K 31/365 - Lactones
• A01N 25/04 - Dispersions ou gels

Abrégé

The present invention relates to a catalytic formulation used in the hydroprocessing of light and middle oil fractions, preferably in hydrodesulfurization and hydrodenitrogenation reactions to obtain diesel with ultra low sulfur content less than or equal to 15 ppm in weight. The catalytic formulation, object of the present invention, consists of at least one metal of Group VI B and at least one metal of Group VIII B and one element of Group V A of the periodic table deposited on a support based on surface modified alumina with an inorganic oxide of a metal of Group II A, IV A and/or IV B. And containing an impregnated organic compound containing at least one hydroxyl group and at least one carboxyl group and that can contain or not at least one sulfide group in its structure. The catalytic formulation, object of the present invention, allows processing of the oil fractions with initial and final boiling temperatures between 150 and 450° C., with initial nitrogen and sulfur content between 1 and 3% by weight and 200 to 600 ppm, respectively, reducing sulfur content to concentrations lower or equal to 15 ppm and nitrogen concentrations to lower than 1 ppm.

Classes IPC  ?

• B01J 27/19 - Molybdène
• B01J 23/85 - Chrome, molybdène ou tungstène
• C10G 45/08 - Raffinage des huiles d'hydrocarbures au moyen d'hydrogène ou de composés donneurs d'hydrogène pour éliminer des hétéro-atomes sans modifier le squelette de l'hydrocarbure mis en œuvre et sans craquage en hydrocarbures à point d'ébullition inférieurHydrofinissage caractérisé par le catalyseur utilisé contenant du nickel ou du cobalt, ou leurs composés en combinaison avec du chrome, du molybdène ou du tungstène, ou leurs composés
• C10L 1/08 - Combustibles carbonés liquides à base essentielle de mélanges d'hydrocarbures pour allumage par compression
• B01J 31/22 - Complexes organiques
• B01J 37/00 - Procédés de préparation des catalyseurs, en généralProcédés d'activation des catalyseurs, en général
• B01J 37/08 - Traitement thermique
• B01J 37/02 - Imprégnation, revêtement ou précipitation
• B01J 35/10 - Catalyseurs caractérisés par leur forme ou leurs propriétés physiques, en général solides caractérisés par leurs propriétés de surface ou leur porosité
• B01J 23/883 - Molybdène et nickel
• B01J 35/02 - Catalyseurs caractérisés par leur forme ou leurs propriétés physiques, en général solides
• C10G 45/06 - Raffinage des huiles d'hydrocarbures au moyen d'hydrogène ou de composés donneurs d'hydrogène pour éliminer des hétéro-atomes sans modifier le squelette de l'hydrocarbure mis en œuvre et sans craquage en hydrocarbures à point d'ébullition inférieurHydrofinissage caractérisé par le catalyseur utilisé contenant du nickel ou du cobalt, ou leurs composés
• B01J 37/20 - Sulfuration

Abrégé

The invention relates to a two-wheeled foldable vehicle comprising seven essential systems: a frame system as the structure of the foldable vehicle, the main functions of which system are to provide support for the other systems, withstand loads and provide an aesthetic display; a saddle or seat system, the main functions of which are to provide a user with comfort and support; a steering system for changing the trajectory of the foldable vehicle; a transmission system for transforming the pedalling of the user into the linear movement of the foldable vehicle; a front hubless wheel system which supports the front portion of the foldable vehicle, in particular the steering system, and which assists the linear movement of the foldable vehicle; a rear hubless wheel system, wherein the rear wheel is the traction wheel of the foldable vehicle and provides the main support for the user; and a folding system that permits the foldable vehicle to be folded or unfolded, transferring same from a storage position to an operative mode-of-transport position, and vice versa.

Classes IPC  ?

• B62K 15/00 - Cycles pliants ou repliables

Abrégé

The invention relates to a method for obtaining a dosimeter in the form of a pellet from material obtained from optical fibres of silicon oxide for the measurement of gamma radiation fields, obtaining a linear response range between 0.1 Gy and 5000 Gy. Pelleting is performed using a mechanical process and a thermoluminescent material. In particular, the invention is used to obtain a dosimeter for gamma radiation, with improved dosimetric characteristics compared to Harshaw TLD dosimeters and providing an improved response to gamma radiation in terms of efficiency, reproducibility, stability, easy management, mechanical and thermal roughness, as well as offering advantages associated with size since it is possible to obtain pellets of diameters of less than 0.5cm.

Classes IPC  ?

• G01T 1/11 - Dosimètres thermo-luminescents

Abrégé

The invention relates to a transdermal patch with excellent physicochemical characteristics such as: breaking strength, bioadhesion, post-wetting bioadhesion, thickness, chemical content and suitable in vitro dissolution speed, which ensures the suitable release of the active substance in order for same to carry out its therapeutic effect. The patch according to the present invention comprises a polymer matrix with chitosan and a poloxamer, in addition to an active principle and a microneedle, and it is applied directly to the skin of the human patient. The patch satisfies the properties of compatibility in the formulation, and chemical stability, it is non-irritating, it does not render the skin sensitive or cause the build-up of sebaceous material, it is not phototoxic, it is inodorous and colourless, it has good breaking strength and it is bioadhesive.

Classes IPC  ?

• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
• A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine

Abrégé

The invention relates to the compounds 3-(1´,1´ -dimethylallyl)-herniarin (1) y 3- (1,1´-dimethyl-3´ nitro allyl-herniarin] (3) (NHR) derived from coumarin, which have excellent antidepressant activity. The compound 3- (1,1´-dimethyl-3´ nitro allyl-herniarin] (3) (NHR) is synthesised by means of a nitration reaction of the compound 3-(1´,1´-dimethylallyl)-herniarin. The present invention also relates to the method for the isolation and synthesis of the compound 3 -(1´,1´-dimethylallyl)-herniarin.

Classes IPC  ?

• C07D 311/50 - Benzo [b] pyrannes non hydrogénés dans le carbocycle avec des atomes d'oxygène ou de soufre en positions 2 et 4 avec un atome d'hydrogène en position 3 non substitués dans le carbocycle avec des éléments autres que le carbone et l'hydrogène en position 3
• A61K 31/37 - Coumarines, p. ex. psoralène
• A61P 25/24 - Antidépresseurs

Abrégé

The invention relates to synthetic peptides derived from the C-terminal of the isoform of the CETP protein, called CETPI, that have the capacity to be molecules blocking the cytotoxic effect induced by lipopolysaccharides both in vitro and in vivo. The invention also relates to immunoenzymatic methods for detecting and quantifying the CETPI protein, using the polyclonal anti-CETPI A481-P491 antibody allowing the control and verification of the blocking of the cytotoxic effect of the polysaccharides.

Classes IPC  ?

• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 31/00 - Agents anti-infectieux, c.-à-d. antibiotiques, antiseptiques, chimiothérapeutiques

Abrégé

The present invention provides a novel vaccine compound of micellar nanoparticles to be administered intranasally to treat and/or prevent the disease called atherosclerosis, which results from an abnormal metabolism of circulating lipids. The novelty of the vaccine compound of the present invention is the use of Archaebacterian lipids, lysophosphatidylcholine, and phosphatidylcholine, which give nanoparticles stability and facilitates antigen presentation in its appropriate secondary peptidic conformation. A novel process for the preparation of vaccine compounds which allows obtaining homogeneous nanoparticles with high stability is also presented in this invention.

Classes IPC  ?

• A61K 35/74 - Bactéries
• A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/107 - Émulsions
• A61K 38/08 - Peptides ayant de 5 à 11 amino-acides

Abrégé

The present invention relates to the preparation of catalysts used in the hydrodesulfurization of fossil fuels and proposes a method for preparing thermally stable, low-cost catalysts for the hydrodesulfurization of petrol and diesel, based on highly active CoMo and NiMo. The catalyst for the hydroprocessing of gasoil or petrol in the present invention comprises a precursor which consists of chemical compounds obtained from organic acids and metal salts, and a support containing an ultra-stable Y-type zeolite useful in the hydroprocessing of heavy gas oil and/or light cyclic gas oil with high conversion rates.

Classes IPC  ?

• B01J 21/04 - Alumine
• B01J 23/28 - Molybdène
• B01J 23/30 - Tungstène
• B01J 23/75 - Cobalt
• B01J 23/755 - Nickel
• B01J 29/16 - Zéolites aluminosilicates cristallinesLeurs composés isomorphes du type faujasite, p. ex. du type X ou Y contenant de l'arsenic, de l'antimoine, du bismuth, du vanadium, du niobium, du tantale, du polonium, du chrome, du molybdène, du tungstène, du manganèse, du technétium ou du rhénium
• C10G 45/12 - Raffinage des huiles d'hydrocarbures au moyen d'hydrogène ou de composés donneurs d'hydrogène pour éliminer des hétéro-atomes sans modifier le squelette de l'hydrocarbure mis en œuvre et sans craquage en hydrocarbures à point d'ébullition inférieurHydrofinissage caractérisé par le catalyseur utilisé contenant des alumino-silicates cristallins, p. ex. des tamis moléculaires
• B01J 23/882 - Molybdène et cobalt
• B01J 23/883 - Molybdène et nickel
• B01J 23/888 - Tungstène
• B01J 27/049 - Sulfures avec du chrome, du molybdène, du tungstène ou du polonium avec des métaux du groupe du fer ou des métaux du groupe du platine
• B01J 27/051 - Molybdène
• B01J 35/00 - Catalyseurs caractérisés par leur forme ou leurs propriétés physiques, en général
• B01J 35/10 - Catalyseurs caractérisés par leur forme ou leurs propriétés physiques, en général solides caractérisés par leurs propriétés de surface ou leur porosité
• B01J 37/02 - Imprégnation, revêtement ou précipitation
• C10G 45/08 - Raffinage des huiles d'hydrocarbures au moyen d'hydrogène ou de composés donneurs d'hydrogène pour éliminer des hétéro-atomes sans modifier le squelette de l'hydrocarbure mis en œuvre et sans craquage en hydrocarbures à point d'ébullition inférieurHydrofinissage caractérisé par le catalyseur utilisé contenant du nickel ou du cobalt, ou leurs composés en combinaison avec du chrome, du molybdène ou du tungstène, ou leurs composés
• B01J 37/08 - Traitement thermique
• B01J 37/20 - Sulfuration

Abrégé

The invention relates to methods for obtaining hydroxyapatite from bone, which has a percentage crystallinity similar to certified standard samples, making it a high-quality product. The process described comprises steps involving primary cleaning of the starting material, fat removal, deproteinization and, optionally, elimination of carbonates. The process of the invention can be used to obtain hydroxyapatite having physicochemical characteristics comparable to commercial hydroxyapatites, as well as including the elements that naturally characterise bone tissue.

Classes IPC  ?

• A61L 27/02 - Matériaux inorganiques
• A61L 27/12 - Matériaux contenant du phosphore, p. ex. apatite
• A61L 27/32 - Matériaux contenant du phosphore, p. ex. apatite

Abrégé

The invention relates specifically to the chemical synthesis, identification and determination of the chemical structure of analogues of the caffeic acid phenethyl ester (CAPE) with activity against cancer, especially against liver cancer. The invention also relates to the production of pharmaceutical compositions containing same and to the use thereof for preventing and treating cancer by means of the chemoprotective capacity thereof.

Classes IPC  ?

• C07D 213/56 - Amides
• A61K 31/165 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide
• C07C 233/11 - Amides d'acides carboxyliques ayant des atomes de carbone de groupes carboxamide liés à des atomes d'hydrogène ou à des atomes de carbone acycliques ayant les atomes d'azote des groupes carboxamide liés à des atomes d'hydrogène ou à des atomes de carbone de radicaux hydrocarbonés non substitués avec des atomes de carbone de groupes carboxamide liés à des atomes de carbone d'un squelette carboné non saturé contenant des cycles aromatiques à six chaînons

Abrégé

The invention relates to the field of multi-etiological molecular diagnosis and diagnosis of emerging diseases through the use of DNA arrays. More specifically, the invention relates to oligonucleotides included in an array for the detection of microorganisms that can cause diarrheal disease. Said array contains the oligonucleotides corresponding to Enteroaggregative Escherichia coli, Enterohemorrhagic Escherichia coli, Enterotoxigenic Escherichia coli, Enteropathogenic Escherichia coli, Enteroinvasive Escherichia coli, Giardia intestinalis, Blastocystis hominis, Entamoeba histolytica/dispar, Cryptosporidium parvum, Shigella spp., Uropathogenic Escherichia coli, Salmonella enterica, Vibrio cholerae, among other pathogens that cause gastric diseases in humans or animals. The array consists in immobilising said oligonucleotides in a support once they have been amplified using the PCR technique. The array can be a microarray or a macroarray, and, in one embodiment, it takes the form of a biochip, either a macrochip or microchip.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
• C12R 1/19 - Escherichia coli
• C12R 1/63 - Vibrio
• C12R 1/00 - Micro-organismes

Abrégé

The invention specifically relates to a pharmaceutical system for producing solid pharmaceutical forms for the administration of therapeutic substances, improving the bioavailability thereof. The system is especially suitable for administering active substances which are sensitive due to the proteinic nature thereof or because they are nucleic acids, as polymer excipients with good matrix and bioadhesion properties are used, which, combined with the impermeability provided by the coating applied, ensure that the system according to the invention is a form of administration with excellent performance.

Classes IPC  ?

• A61K 9/22 - Pilules, pastilles ou comprimés du type à libération prolongée ou discontinue

Abrégé

The invention relates to an optical switch having an operating principle based on tilting and/or deforming a reflector element or a movable refractor having flexible supporting elements of the beam, coil, bar, etc. type, and electrostatic and/or electromagnetic actuation. The path of an input beam is modified by means of a mobile reflector or refractor element that tilts in various positions, thereby switching one or more input light beams to one or more output ports. Multiple switches of said type can also be arranged in series or in parallel in order to increase the number of input and output ports. The invention meets the needs of optical switching in computer data networks and in optical sensor networks, as most important uses.

Classes IPC  ?

• G02B 26/08 - Dispositifs ou dispositions optiques pour la commande de la lumière utilisant des éléments optiques mobiles ou déformables pour commander la direction de la lumière

Abrégé

The invention relates to a method for producing of dimensionally stable Ti/TiO2/RuO2/SnO2-Sb2O5-RuO2 electrodes (anodes), which comprises the following stages: I. preparing the metallic support-base, made of Micro Grade 1 titanium, wherein said support may be in the shape of a plate or mesh; II. applying, to the metal support, a first coating of titanium oxide (TiO2) on top of the first coating; III. applying, to the metal support, a second coating of ruthenium oxide (RuO2) on top of the second coating; and, IV. applying, to the metal support, a third coating of a ternary mixture of metal oxide precursors of SnO2-Sb2O5-RuO2, on top of said second and first coatings. In addition, the invention relates to dimensionally stable electrodes (anodes) (DSA) of Ti/TiO2/RuO2/SnO2-Sb2O5-RuO2, directly obtained from the method of the present invention, which are used for wastewater treatment.

Classes IPC  ?

• C25B 11/10 - Electrodes à base de métaux à couche d'arrêt, p.ex. titane

Abrégé

The invention relates to a method for producing a composite aluminosilicate material containing alumina and zeolite. The composite is obtained by means of hydrothermal zeolite synthesis in a macroheterogeneous system in the presence of alumina, which serves as both a reaction component and a support for the resulting zeolite. In the case of the zeolite faujasite (Y) the material obtained is characterised in that it contains a high proportion of zeolite, retaining the large volume of mesopores in the hierarchical porosity of the composite, and nanozeolite crystals that have a high SiO2/Al2O3 ratio.

Classes IPC  ?

• C01B 39/24 - Type Y
• B82Y 30/00 - Nanotechnologie pour matériaux ou science des surfaces, p. ex. nanocomposites

Abrégé

The invention relates to a composition comprising ranitidine, nopal mucilage (as a natural controlled-release vehicle with gastric mucosa regenerative properties) and a wetting agent, for use in the treatment of gastric disorders, such as gastric ulcers, active duodenal ulcers, Zollinger–Ellison syndrome, gastro-oesophageal reflux and erosive oesophagitis.

Classes IPC  ?

• A61K 36/33 - Cactaceae (famille du cactus), p. ex. figue de Barbarie ou Cereus
• A61K 31/341 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide non condensés avec un autre cycle, p. ex. ranitidine, furosémide, bufétolol, muscarine
• A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse

Abrégé

The invention relates to an improved long-acting or extended-release tilmicosin formulation comprising: tilmicosin phosphate in a concentration between 35 and 50% by weight of the total composition; a first cosolvent in a concentration between 8 and 20% by volume, said first cosolvent being propylene glycol; a second cosolvent in a concentration between 5 and 15% by volume, said second cosolvent being ethyl alcohol; and an emulsifier in a concentration between 1.5 and 15% by weight of the total composition, said emulsifier being poloxamer. The invention also relates to the method for producing said improved long-acting tilmicosin formulation.

Classes IPC  ?

• A61K 31/706 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle
• A61P 31/04 - Agents antibactériens

Abrégé

The invention relates to a biodegradable polymer system for formulating hydrophilic sensitive drugs such as peptides and proteins. The systems are assembled by means of the adsorption of biodegradable polymer nanoparticles in biodegradable porous microspheres using an adsorption/infiltration process. The drug is not involved in the production of the nanoparticles or in the production of the microspheres and, consequently, contact with organic solvent, interfaces and shear forces are all prevented during drug loading. The drug is adsorbed onto different quantities of nanoparticles which are infiltrated into the porous microspheres. The adsorption efficacy and the release speed depend on the quantity of nanoparticles adsorbed/infiltrated. The method can be used as a possible alternative for formulating hydrophilic sensitive drugs.

Classes IPC  ?

• A61K 9/50 - Microcapsules
• A61K 9/51 - Nanocapsules
• A61K 38/00 - Préparations médicinales contenant des peptides

Abrégé

The invention relates to an air scrubber for scrubbing air of volatile organic compounds and microparticles, including a dual-function motor that drives a water pump and an air extractor which conveys molecules of burnt oil and fat fumes, microparticles of dust and volatile organic compounds through a duct to a column reactor, into which a counter flow of aqueous scrubbing suspension arrives from a mixing tank. The aqueous scrubbing suspension is a mixture of a microporous material, natural zeolite (clinoptilolite) or nanoparticles of a metal oxide. The power source of the air scrubbing motor can be electric, a photovoltaic system with a plurality of solar panels, a wind powered generator, etc.

Classes IPC  ?

• B01D 47/06 - Nettoyage par pulvérisation
• B01D 47/14 - Absorbeurs à remplissage

Abrégé

The biphasic extraction from coffee waste without a prior drying process, to obtain coffee oil, which is transesterified with KOH catalyzed methanol to produce mixtures of glycerol free methylic esters, also known as coffee oil biodiesel, which is subjected to an aminolysis reaction with aminoethylethanolamine (AEEA) by heating to 140-160° C. at atmospheric pressure with a subsequent dehydration reaction at the same temperature but at a reduced pressure of 200 to 300 mmHg, in order to achieve cyclization of the intermediary amides into the corresponding imidazolines. Alternatively process, coffee oil can be submitted to the same aminolysis procedure with aminoethylethanolamine (AEEA) at 140 to 160° C. and atmospheric pressure with a subsequent dehydration reaction at the same temperature but at a reduced pressure of 200 to 300 mmHg, to produce imidazolines that contain the residual glycerol of the original triglycerides.

Classes IPC  ?

• C07D 233/06 - Composés hétérocycliques contenant des cycles diazole-1, 3 ou diazole-1, 3 hydrogéné, non condensés avec d'autres cycles comportant une liaison double entre chaînons cycliques ou entre chaînon cyclique et chaînon non cyclique avec uniquement des atomes d'hydrogène ou des radicaux ne contenant que des atomes d'hydrogène et de carbone, liés directement aux atomes de carbone du cycle
• C07D 233/14 - Radicaux substitués par des atomes d'oxygène
• C23F 11/14 - Composés contenant de l'azote
• C05F 5/00 - Engrais fabriqués à partir de déchets de distillerie ou de sucreries, de mélasses, vinasses ou de déchets ou résidus similaires

Abrégé

The invention relates to a recrystallised dehydrated enrofloxacin hydrochloride complex of formula (I) wherein the acid recrystallisation and formation of complexes with chloride, magnesium and sulfate produce a highly-soluble recrystallised enrofloxacin hydrochloride which provides, subcutaneously, maximum serum concentrations (Cmax) and areas under the curve (AUC) of concentration vs. time larger than those achieved with the basic enrofloxacin.

Classes IPC  ?

• C07D 215/56 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène liés en position 3 avec des atomes d'oxygène en position 4
• A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles

Abrégé

The present invention relates to a thermoplastic elastomer compound which is electrically conductive and capacitive and is based on the combination of a polymer matrix which acts as a binding agent, in addition to being used as a matrix or substrate; a nanostructured electrically conductive compound, which has the function of conducting electricity by means of transporting electrons; and a compatibilising compound and ion conductor, the main function of which is to ensure the compatibility of the "first two components, one dispersing in the other, in addition to conducting the electricity by ion transport". According to the invention, said elastomer compound is useful mainly in the electronics industry, and preferably in the production of thin flexible rechargeable polymer batteries.

Classes IPC  ?

• C08L 79/02 - Polyamines
• C08L 101/12 - Compositions contenant des composés macromoléculaires non spécifiés caractérisées par des propriétés physiques, p. ex. anisotropie, viscosité ou conductivité électrique
• H01B 1/12 - Conducteurs ou corps conducteurs caractérisés par les matériaux conducteurs utilisésEmploi de matériaux spécifiés comme conducteurs composés principalement d'autres substances non métalliques substances organiques
• B82Y 30/00 - Nanotechnologie pour matériaux ou science des surfaces, p. ex. nanocomposites

Abrégé

The invention relates to a novel test for the in vitro diagnosis of fibrosis during liver disease, using the determination of non-invasive biomarkers which allow the opportune and early detection of the process which determines the degree of damage of the organ. The panel of non-invasive biomarkers of the present invention also allows liver fibrosis to be staged, facilitating the most appropriate choice of treatment for the subject.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The invention relates to an orthotic device for assisting with bending and extending movements of the fingers of a hand, for patients suffering from paralysis of the brachial plexus, said device comprising an opening and closing mechanism used to convert a linear movement (input) into the actual movement of a bent finger (output); a forearm support which, as its name suggests, is used to support the forearm of a user suffering from brachial paralysis, as well as supporting the opening and closing mechanism; a sub-assembly for transmitting the bending/extending movement, which is interconnected with the opening and closing mechanism via a first cable, and with a vest fitted to the chest of the user, via the outlet of a second cable; and a support for the thumb of the hand, which is secured to the forearm support, and said support is used to keep said thumb immobilised.

Classes IPC  ?

• A61F 5/01 - Dispositifs orthopédiques, p. ex. dispositifs pour immobiliser ou pour exercer des pressions de façon durable pour le traitement des os fracturés ou déformés, tels que éclisses, plâtres orthopédiques ou attelles

Abrégé

The invention relates to non-invasive biomarkers coupled to spheres operating as solid supports in a multiple arrangement, used in the detection, prognosis and monitoring of the fibrogenic process.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques

Abrégé

The invention relates to an ophthalmological device for the quality control of corneal tissue for transplant purposes, which is placed on the pedestal, better known as a chin rest, of a slit lamp. The device, with its parts and the connection of these parts, mainly a support for a container ring and a 45-degree prism or mirror, allows observation, for the purpose of analysis, of the procured corneal tissue over the entire length thereof, said corneal tissue being housed in a sterile transport container also containing the preservation solution. The device can be used to analyse procured corneal tissues, maintaining the original characteristics, i.e. it allows an analysis to be carried out as if it were a tissue not procured for the subsequent transplant thereof.

Classes IPC  ?

• A61B 3/135 - Microscopes à lampe à fente
• A01N 1/02 - Conservation de parties vivantes

Abrégé

The invention relates to a method for preparing a polymer material with a network structure controlled on the basis of synthesis methods derived from reversible-deactivation radical polymerisation (RDRP) in compressed fluids. The polymer material of the invention includes a network structure controlled in size and periodicity which allows it to have properties of capturing, storing, releasing or retaining various substances such as: drugs, fragrances, flavourings, food supplements, vitamins, antioxidants, essences, sun blocks, insect repellents, fertilisers, insecticides, etc., as well as having improved structural and performance properties, compared to the materials produced by the traditional polymerisation techniques that do not use an RDRP controller or compressed fluids simultaneously.

Classes IPC  ?

• C08F 2/12 - Polymérisation en milieu non solvant
• C08F 2/38 - Polymérisation utilisant des régulateurs, p. ex. des agents d'arrêt de chaîne
• C08F 220/06 - Acide acryliqueAcide méthacryliqueLeurs sels métalliques ou leurs sels d'ammonium
• C08F 212/08 - Styrène

Abrégé

The invention relates to the production and the characterisation of new murine monoclonal antibodies that recognise the domain CTDL-2 (SEQ ID NO: 1) of the cell receptor DEC-205 of dendritic cells in chickens (Gallus gallus), pigs, (Sus scrofa) and humans (Homo sapiens). The invention also relates to the capacity of the new antibodies to direct and modulate the immune response at different levels in chickens (Gallos gallus) and pigs (Sus scrofa), as well as recognising the receptor DEC-205 in dentritic cells and cell lines in humans. In addition, the invention is used to quickly produce a specific humoral immune response against Hemaglutinina H5 of the H5N2-type avian flu virus.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire

Abrégé

The invention relates to orthodontic adhesives formulated with trimethylolpropane trimethacrylate (TMPTMA) that do not contain BisGMA. More specifically, the invention relates to adhesive pastes characterised in that they have an organic phase comprising the trimethylolpropane trimethacrylate monomer, camphorquinone as a photoinitiator, dimethyl-p-toluidine as an accelerator, and an inorganic phase comprising manometer particle-size silanised silicon dioxide together with micrometer particle-size silanised silicon dioxide. Said adhesives are produced by means of successive mixing and homogenisation of the components in chambers under safe light conditions.

Classes IPC  ?

• A61K 6/08 - Emploi de résines naturelles ou synthétiques
• A61L 27/14 - Matériaux macromoléculaires
• A61L 24/04 - Adhésifs ou ciments chirurgicauxAdhésifs pour dispositifs de colostomie contenant des matériaux macromoléculaires
• A61L 24/02 - Adhésifs ou ciments chirurgicauxAdhésifs pour dispositifs de colostomie contenant des matériaux inorganiques
• A61C 13/00 - Prothèses dentairesLeurs procédés de fabrication
• A61C 5/00 - Obturation ou recouvrage des dents

Abrégé

Bioinspired antifungal systems. The invention relates to novel systems based on substrates containing covalently bonded ergosterol molecules that can comprise antifungal compounds imitating the joining of the antifungal agent to the wall of the fungi. When the systems of the invention loaded with antifungal agents are in the presence of fungi, the transfer process is accelerated as a competition is established for the antifungal agent between the ergosterol of the systems of the invention and the ergosterol of the wall of the fungi. The systems according to the invention are useful for the prevention of colonisation by fungi and/or for the treatment of infections by fungi, in applications such as systems for the release of antifungal active substances, and packagings or coverings for work surfaces.

Classes IPC  ?

• C07J 9/00 - Stéroïdes normaux contenant du carbone, de l'hydrogène, un halogène ou de l'oxygène, substitués en position 17bèta par une chaîne de plus de deux atomes de carbone, p. ex. cholane, cholestane, coprostane
• C08G 77/04 - Polysiloxanes
• A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol

Abrégé

The invention relates to the use of adenosine aspartate for the differential activation of macrophages in inflammatory-fibrogenic processes and the reversion thereof.

Classes IPC  ?

• A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p. ex. adénosine, acide adénylique
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]

Abrégé

The invention relates to the use of a recombinant protein in order to induce the expression of interleukin 10, in which the protein is recombinant calreticulin of the parasite Taenia solium (rTsCRT) formulated in a physiological glucose solution administered orally or parenterally. The methodology used for the expression and purification of the rTsCRT as described in the present invention resulted in a recombinant protein expressed without post-transduction modifications, which has immune regulation effects and can stimulate the transcription levels of the mRNA that code for cytokines IL-4 and IL-10. The rTsCRT was expressed in an unlabelled E. coli system, although it can be applied to any expression system, whether in prokaryotic or eukaryotic cells. The rTsCRT is produced so that it can be used for the treatment of local and systemic inflammatory diseases.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains

Abrégé

The invention relates to a bovine gynaecological exam simulator for diagnosis of the oestrous cycle, which allows the user to perform simulations that imitate or simulate the sensory and physiological conditions that a veterinarian experiences while performing a bovine gynaecological exam in order to diagnose the oestrous cycle by means of rectal palpation on a real female bovine. In addition, the simulator of the invention can be used to record and store the pressure exerted by the user while palpating a real or artificial bovine ovary, while providing feedback in real time by means of a graphical interface.

Classes IPC  ?

• G09B 23/36 - Modèles à usage scientifique, médical ou mathématique, p. ex. dispositif en vraie grandeur pour la démonstration pour la zoologie
• A61D 17/00 - Dispositifs pour signaler des troubles pendant que l'animal est en travail